Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025Journal of Managed Care & Specialty Pharmacy

Real-world costs, treatment patterns, and clinical outcomes associated with treatments for advanced anaplastic lymphoma kinase–positive non–small cell lung cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

RMRahul MudumbaUniversity of Southern CaliforniaXLXiao Fan LiuCity University of Hong KongIDIan DavisUniversity of Southern California

Discussion

Loading...

Member takes

Implication

Observational analysis evaluates treatment patterns and clinical outcomes for ALK-positive NSCLC patients, indicating economic challenges.

Key Points

  • Patients with advanced ALK+ non-small cell lung cancer exhibited high treatment discontinuation rates, highlighting a significant clinical challenge.
  • Total per-patient-per-month costs for treatments were around $28,216, suggesting substantial economic implications for healthcare systems.
  • Overall survival (OS) for patients receiving first-line therapies was a median of 25.5 months, underlining the effectiveness of chosen treatments.
  • A retrospective cohort study was conducted using real-world data from the Clinformatics Data Mart Database over five years, providing insights into treatment efficacy.

Cite This Study

Mudumba et al. (2025) studied this question.

synapsesocial.com/papers/68bb46bd6d6d5674bccfeb92https://doi.org/10.18553/jmcp.2025.31.9.890
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician2018 · 743 citations
  2. 2Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC2024 · 11 citations
  3. 3Real-World Treatment and Outcomes in ALK-Rearranged NSCLC: Results From a Large U.S.-Based Database2024 · 9 citations
  4. 4Quasi-Experimental Designs for Causal Inference2016 · 131 citations
  5. 5An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non–Small-Cell Lung Cancer2019 · 137 citations